FDA Approves Pimicotinib for Treatment of Rare Joint Tumors

The United States Food and Drug Administration has officially approved pimicotinib, marketed as Pimjetmi, for the treatment of adult patients with symptomatic tenosynovial giant cell tumors. This rare, locally aggressive condition develops in or around joints and often leads to progressive swelling, stiffness, and reduced mobility. The approval specifically targets patients for whom surgical removal of the tumor could cause severe health complications or significant functional limitations. The medication is administered as a once-daily oral dose of 50 milligrams, which patients can take with or without food. This regulatory decision follows the results of the global phase 3 MANEUVER clinical trial. The study was a randomized, double-blind, placebo-controlled investigation that evaluated the drug's efficacy in patients who had not previously received similar systemic therapies. Researchers focused on how well the drug could reduce tumor size while improving the physical quality of life for participants. The trial successfully met its primary endpoint by demonstrating deep and durable tumor responses in those receiving the treatment. Data from the MANEUVER trial showed that patients treated with pimicotinib achieved an overall response rate of 54 percent at week 25, compared to only 3.2 percent for those in the placebo group. With longer follow-up periods, these responses were shown to deepen, reaching an overall response rate of 76.2 percent. These findings suggest that the drug provides a significant therapeutic benefit for individuals struggling with the debilitating effects of these tumors. Beyond tumor reduction, the study measured improvements in secondary outcomes such as pain, stiffness, and physical function. Patients reported statistically significant reductions in their worst pain and stiffness levels compared to the placebo group. Furthermore, participants showed meaningful improvements in their active range of motion and overall physical function as measured by standardized health scales. These results highlight the potential for the drug to restore mobility in patients who previously had few effective treatment options. Niu Xiaohui, the director of the Bone and Soft Tissue Tumour Diagnosis and Research Centre at Beijing Jishuitan Hospital, noted the significance of these findings. He stated that the MANEUVER trial observed the highest overall response rate seen to date with a systemic therapy for this condition. He emphasized that the improvements in pain and range of motion provide a clear clinical benefit for patients. The trial results were recently published in the medical journal Lancet. The FDA had previously granted the drug breakthrough therapy and fast track designations to expedite its development. The application was also reviewed under Project Orbis, an initiative that allows for concurrent submission and review of oncology products among international regulatory agencies. Pimicotinib had already received approval for use in China in December 2025. This international cooperation aims to bring innovative cancer treatments to patients across the globe more efficiently. While the drug offers a new path for treatment, medical professionals are advised to monitor patients for common adverse reactions. According to the FDA, the most frequently reported side effects include rash, facial edema, and pruritus. These reactions occurred in more than 20 percent of patients during the clinical trials. Healthcare providers will continue to track these outcomes as the drug becomes more widely available in clinical settings. The approval of pimicotinib represents a shift in how clinicians manage aggressive, non-malignant joint tumors. By targeting the underlying biological pathways that drive tumor growth, the medication provides a non-surgical alternative for those at risk of severe morbidity. This development is expected to change the standard of care for patients who cannot undergo traditional surgical resection. Future research will likely continue to explore the long-term safety and efficacy of this therapy in diverse patient populations.